benzbromarone drug combination allopurinol

01/01/2014 - "Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients."
04/15/2017 - "Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study."
08/31/1979 - "[Allomaron in hyperuricemia and gout]."
08/01/2002 - "Sixty-three patients with crystal-confirmed tophaceous gout were treated with allopurinol, benzbromarone, or combined therapy to achieve serum uric acid levels less than the threshold for saturation of urate in tissues. "
09/01/2014 - "Trials covered treatment with allopurinol, benzbromarone, rasburicase, or febuxostat in a gout population with mild or moderate renal insufficiency. "

09/01/1994 - "It is concluded that in hyperuricemia up to 0.37 +/- 0.02 mmol/l allomaron is more effective (1--2 pills a day). "
01/01/1994 - "[The use of Allomaron in treating hyperuricemia]."
08/31/1979 - "[Allomaron in hyperuricemia and gout]."
09/01/1994 - "[The correction of hyperuricemia in patients with different forms of nephrolithiasis using allopurinol and Allomaron]."
09/01/2004 - "To compare the efficacy of combined low dose of hypouricemic drugs (Allopurinol 100 mg and benzbromarone 20 mg; Allomaron) and standard dose 300 mg of allopurinol in hyperuricemia. "

09/01/2014 - "Trials covered treatment with allopurinol, benzbromarone, rasburicase, or febuxostat in a gout population with mild or moderate renal insufficiency. "
09/01/2014 - "In gout patients with renal insufficiency febuxostat, rasburicase, benzbromarone, and allopurinol + benzbromarone seemed to be effective and safe; allopurinol may be cautiously titrated until the target uric acid level has been reached, and may improve renal function."

04/15/2017 - "Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study."

09/01/1994 - "[The correction of hyperuricemia in patients with different forms of nephrolithiasis using allopurinol and Allomaron]."